🇺🇸 FDA
Patent

US 11083720

Indazole inhibitors of fructokinase (KHK) and methods of use in treating KHK-mediated disorders or diseases

granted A61KA61K31/416A61K31/4439

Quick answer

US patent 11083720 (Indazole inhibitors of fructokinase (KHK) and methods of use in treating KHK-mediated disorders or diseases) held by The Regents of the University of Colorado, a Body Corporate expires Mon Aug 05 2041 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The Regents of the University of Colorado, a Body Corporate
Grant date
Tue Aug 10 2021 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Aug 05 2041 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
13
CPC classes
A61K, A61K31/416, A61K31/4439, A61K31/496, A61K31/506